Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report.

Medicine - 1 Nov 2019

Abdou Yara, Kapoor Ankita, Hamad Lamya, Ernstoff Marc S

Abstract excerpt

RATIONALE: The treatment of metastatic melanoma has been revolutionized in the past decade because of the development of immunotherapies and targeted therapies. Despite these developments, there is still an unmet clinical need for more advanced combination therapies for the subset of patients who remain resistant to immunotherapy or targeted therapy alone. To our knowledge, no reports have been published on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Melanoma

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins c-kit

Share to Skin Neoplasms

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 31689840
DOI: 10.1097/MD.0000000000017769
PMCID: PMC6946408

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report.PMID 31689840Read ↗

V559A and N822I double KIT mutant melanoma with predictable response to imatinib?Semantic proximity Read ↗

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma.Semantic proximity Read ↗

Combination therapy of melanoma using kinase inhibitors.Semantic proximity Read ↗

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.Semantic proximity Read ↗

Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).Semantic proximity Read ↗

Cobimetinib and vemurafenib for the treatment of melanoma.Semantic proximity Read ↗

Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.Semantic proximity Read ↗

Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial).Semantic proximity Read ↗

A potential role for nilotinib in KIT-mutated melanoma.Semantic proximity Read ↗

[Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report].Semantic proximity Read ↗

Primary melanoma of the stomach treated by BRAF inhibitor and immunotherapy.Semantic proximity Read ↗

Cobimetinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.